How do you pay?

How to pay the least

Ask for the cash price

Invega Trinza

No generic is sold yet.

  1. Ask your pharmacy for Invega Trinza’s cash price, and one or two other pharmacies too.
  2. Invega Trinza’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Johnson & Johnson Patient Assistance Program. Patients’ income must be equal to or less than 300% of Federal Poverty Level (FPL). Or call 1-833-742-0791.

See if you qualify 

Compare every option

Question
Brand nameInvega Trinza
Authorized genericpaliperidone palmitate
Regular genericpaliperidone palmitate
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone sold yet
Same as Invega Trinza?
The original
–
–

Brand nameThe maker’s card

J&J withMe Savings Program

Savings card from Johnson & Johnson

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $10 a dose

Sign up on jnjwithme.com 

Or call 1-877-227-3728.

In the maker’s words

“Eligible commercially insured patients pay $10 per dose.”

From the maker’s offer on jnjwithme.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Invega Trinza itself, from the same company, sold without the brand name, and usually for less. For now Invega Trinza is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

INVEGA TRINZA, a 3-month injection, is an atypical antipsychotic indicated for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA (1-month paliperidone palmitate extended-release injectable suspension) for at least four months.

Source: the FDA label for Invega Trinza (Janssen Pharmaceuticals, Inc), February 14, 2025. Full label on DailyMed 

Good to know